The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis using Bayesian methods

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2365-2376

  Kwak, Min Sun ^a   Kim, Eunyoung ^b   Jang, Eun Jin ^c   Kim, Hyun Jung ^d   Lee, Chang Hoon ^e  

^a Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^b Kyungpook National University   (South Korea)

^c Andong National University   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Chronic obstructive pulmonary disease (COPD); Inhaled corticosteroids (ICSs); Inhaled long acting muscarinic antagonists (LAMAs); Inhaled long acting 2 agonists (LABAs)

Indexed keywords

ACLIDINIUM BROMIDE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; LONG ACTING DRUG; MOMETASONE FUROATE; SALMETEROL; TIOTROPIUM BROMIDE; TRIAMCINOLONE; VILANTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG COMBINATION;

ACUTE DISEASE; BAYES THEOREM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PNEUMONIA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; ST GEORGE RESPIRATORY QUESTIONNAIRE SCORE; SYSTEMATIC REVIEW; THRUSH; TREATMENT RESPONSE; TRIPLE THERAPY; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; ODDS RATIO; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BAYES THEOREM; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG COMBINATIONS; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; ODDS RATIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; SURVEYS AND QUESTIONNAIRES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84946824940     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S93191     Document Type: Review

References (46)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2014. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed September 19, 2015.
2. Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med. 2014;25(5):491-495.
3. Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2012;25(1):40-47.
4. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-555.
5. Cazzola M, Ando F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther. 2007;20(5):556-561.
6. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91-101.
7. Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration. 2013;86(4):280-287.
8. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382-389.
9. Maltais F, Mahler DA, Pepin V, et al. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J. 2013;42(2):539-541.
10. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741-750.
11. Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KR, Sweeting MJ. Meta-analysis of rare and adverse event data. Exp Rev Pharmacoecon Outcomes Res. 2002;2(4):367-379.
12. National Evidence-based Healthcare Collaborating Agency. Bayesian Meta-Analysis Method. Seoul, Korea: NECA; 2013.
13. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Hoboken, NJ: Wiley; 2000.
14. Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66(2):173-183.
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
16. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000;4(38):1-130.
17. Higgins JP, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane collaboration; 2011.
18. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
19. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med. 2002;21(11):1601-1623.
20. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ. 2008;336(7651):1006-1009.
21. Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457-511.
22. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1997;7:434-455.
23. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119-1129.
24. Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment - difficulties of and barriers to drug development. Lancet. 2011;378(9795):1027-1037.
25. Jones PW. St George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
26. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
27. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5):317-326.
28. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006;27(3):547-555.
29. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171-1178.
30. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948-955.
31. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
32. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81.
34. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
35. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332-338.
36. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
37. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157.
38. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524-533.
39. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med. 2013;107(2):223-232.
40. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511-1520.
41. Karner C, Cates CJ. Long-acting β(2)-agonist in addition to tiotropium versus either tiotropium or long-acting β(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;4:CD008989.
42. Lee CH, Jang EJ, Hyun MK, Lee NR, Kim K, Yim JJ. Risk of hospital admission or emergency room visit for pneumonia in patients using respiratory inhalers: a case-crossover study. Respirology. 2013;18(7):1116-1127.
43. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Syst Rev. 2014;3:CD010115.
44. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.
45. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulm Dis. 2012;7:95-99.
46. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.